Shu, Shaokun <br/><br/>
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.  [electronic resource] 

 -  Nature  Jan 2016 
 - 413-417 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1476-4687 
<br/><br/><label>Standard No.: </label>10.1038/nature16508  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Azepines--pharmacology<br/>Binding, Competitive--drug effects<br/>Casein Kinase II--metabolism<br/>Cell Cycle Proteins<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Chromatin--genetics<br/>Drug Resistance, Neoplasm--drug effects<br/>Epigenesis, Genetic--drug effects<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Genome, Human--drug effects<br/>Humans<br/>Mediator Complex Subunit 1--metabolism<br/>Mice<br/>Nuclear Proteins--antagonists & inhibitors<br/>Phosphorylation--drug effects<br/>Phosphoserine--metabolism<br/>Protein Binding--drug effects<br/>Protein Phosphatase 2--metabolism<br/>Protein Structure, Tertiary--drug effects<br/>Proteomics<br/>Transcription Factors--antagonists & inhibitors<br/>Transcription, Genetic--drug effects<br/>Triazoles--pharmacology<br/>Triple Negative Breast Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays